[go: up one dir, main page]

SI3891145T1 - Modulatorji trex1 - Google Patents

Modulatorji trex1

Info

Publication number
SI3891145T1
SI3891145T1 SI201930577T SI201930577T SI3891145T1 SI 3891145 T1 SI3891145 T1 SI 3891145T1 SI 201930577 T SI201930577 T SI 201930577T SI 201930577 T SI201930577 T SI 201930577T SI 3891145 T1 SI3891145 T1 SI 3891145T1
Authority
SI
Slovenia
Prior art keywords
trex1
modulators
Prior art date
Application number
SI201930577T
Other languages
English (en)
Inventor
Anna Gardberg
Victor S. Gehling
Avinash Khanna
Julian R. Levell
Jonathan E. Wilson
Kennedy Taveras
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of SI3891145T1 publication Critical patent/SI3891145T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Burglar Alarm Systems (AREA)
SI201930577T 2018-12-06 2019-12-06 Modulatorji trex1 SI3891145T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776031P 2018-12-06 2018-12-06
EP19828476.2A EP3891145B1 (en) 2018-12-06 2019-12-06 Modulators of trex1
PCT/US2019/064825 WO2020118133A1 (en) 2018-12-06 2019-12-06 Modulators of trex1

Publications (1)

Publication Number Publication Date
SI3891145T1 true SI3891145T1 (sl) 2023-11-30

Family

ID=69024702

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930577T SI3891145T1 (sl) 2018-12-06 2019-12-06 Modulatorji trex1

Country Status (30)

Country Link
US (2) US12172990B2 (sl)
EP (1) EP3891145B1 (sl)
JP (1) JP7471297B2 (sl)
KR (1) KR20210102310A (sl)
CN (1) CN113396149B (sl)
AU (1) AU2019395005B2 (sl)
BR (1) BR112021010919A2 (sl)
CA (1) CA3122093A1 (sl)
CL (1) CL2021001461A1 (sl)
CO (1) CO2021008816A2 (sl)
CY (1) CY1126082T1 (sl)
DK (1) DK3891145T3 (sl)
EA (1) EA202191519A1 (sl)
ES (1) ES2949999T3 (sl)
FI (1) FI3891145T3 (sl)
HR (1) HRP20230701T1 (sl)
HU (1) HUE062866T2 (sl)
IL (1) IL283672B2 (sl)
LT (1) LT3891145T (sl)
MA (1) MA54386B1 (sl)
MX (1) MX2021006695A (sl)
MY (1) MY207276A (sl)
PE (1) PE20212070A1 (sl)
PH (1) PH12021551317A1 (sl)
PL (1) PL3891145T3 (sl)
PT (1) PT3891145T (sl)
RS (1) RS64336B1 (sl)
SG (1) SG11202105772SA (sl)
SI (1) SI3891145T1 (sl)
WO (1) WO2020118133A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113396149B (zh) 2018-12-06 2024-07-02 星座制药公司 Trex1的调节剂
US20220289728A1 (en) * 2019-07-23 2022-09-15 Constellation Pharmaceuticals, Inc. Modulators of trex1
CA3177376A1 (en) * 2020-05-01 2021-11-04 Julian R. Levell Modulators of trex1
WO2022031640A1 (en) * 2020-08-04 2022-02-10 Wake Forest University Health Sciences Trex1 inhibitors and uses thereof
EP4330254A1 (en) * 2021-04-26 2024-03-06 Constellation Pharmaceuticals, Inc. Modulators of trex1
PH12023553004A1 (en) * 2021-05-05 2024-03-11 Constellation Pharmaceuticals Inc Modulators of trex1
WO2023137030A1 (en) * 2022-01-11 2023-07-20 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1441735T3 (da) 2001-10-26 2006-06-12 Angeletti P Ist Richerche Bio N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
EP1654249A1 (en) 2003-08-07 2006-05-10 Pharmacia & Upjohn Company LLC Anthelmintic and insecticide pyrimidine derivatives
ATE537169T1 (de) 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
EP1954283A2 (en) 2005-11-04 2008-08-13 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
US20110124666A1 (en) * 2008-06-02 2011-05-26 Janssen Pharmaceutica NV a corporation 3,4-dihydropyrimidine trpa1 antagonists
EP2323660A2 (en) 2008-08-08 2011-05-25 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
BR112012007349A2 (pt) * 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
WO2011107494A1 (de) * 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2685982B1 (en) * 2011-03-17 2017-07-05 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
EP2885289A1 (en) 2012-08-06 2015-06-24 Savira Pharmaceuticals GmbH Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019245910A1 (en) 2018-06-22 2019-12-26 Aduro Biotech, Inc. Triazine compounds and uses thereof
CN113396149B (zh) 2018-12-06 2024-07-02 星座制药公司 Trex1的调节剂
CN114341125A (zh) 2019-05-02 2022-04-12 星座制药公司 Trex1调节剂
US20220289728A1 (en) 2019-07-23 2022-09-15 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
IL283672B2 (en) 2024-10-01
DK3891145T3 (da) 2023-07-24
CA3122093A1 (en) 2020-06-11
RS64336B1 (sr) 2023-08-31
EP3891145B1 (en) 2023-04-12
MA54386B1 (fr) 2023-08-31
FI3891145T3 (fi) 2023-07-18
SG11202105772SA (en) 2021-06-29
CN113396149B (zh) 2024-07-02
PT3891145T (pt) 2023-07-18
EA202191519A1 (ru) 2021-10-27
JP2022510431A (ja) 2022-01-26
HUE062866T2 (hu) 2023-12-28
HRP20230701T1 (hr) 2023-10-13
MX2021006695A (es) 2021-09-23
EP3891145A1 (en) 2021-10-13
IL283672A (en) 2021-07-29
US20250136588A1 (en) 2025-05-01
US20220017502A1 (en) 2022-01-20
AU2019395005A1 (en) 2021-06-17
MA54386A (fr) 2021-10-13
CY1126082T1 (el) 2023-11-15
LT3891145T (lt) 2023-08-10
BR112021010919A2 (pt) 2021-08-24
JP7471297B2 (ja) 2024-04-19
CL2021001461A1 (es) 2021-12-17
CN113396149A (zh) 2021-09-14
PL3891145T3 (pl) 2023-08-07
MY207276A (en) 2025-02-13
US12172990B2 (en) 2024-12-24
PE20212070A1 (es) 2021-10-26
CO2021008816A2 (es) 2021-07-19
AU2019395005B2 (en) 2025-06-05
PH12021551317A1 (en) 2022-05-16
KR20210102310A (ko) 2021-08-19
WO2020118133A1 (en) 2020-06-11
ES2949999T3 (es) 2023-10-04
IL283672B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
IL283672A (en) trex1 modulators
IL275482A (en) Asketamine for the treatment of depression
IL259421B (en) ror - gamma modulators
IL274745A (en) Complementary system activity modulators
PL3743406T3 (pl) Modulatory tmem16a
IL304618A (en) Modulators of pcsk9 expression
IL289861A (en) trex1 modulators
SG11202106378VA (en) Modulators of hsd17b13 expression
SG11202102636UA (en) Modulators of pnpla3 expression
GB2576056B (en) Modulators
ZA202007537B (en) Modulators of apol1 expression
IL266641A (en) Complementary system activity modulators
IL285333A (en) Modulators of malat1 expression
GB201700711D0 (en) Application of an optical effect
IL277847A (en) Modulators of EZH2 expression
IL287684A (en) trex1 modulators
GB2585587B (en) Modulators
SG11201911313YA (en) Modulators of alpha-synuclein
SG11202105136WA (en) Application of chidamide
HK40075183A (en) Modulators of trex1
HK40070561A (en) Modulators of trex1
IL271332A (en) Tetrahydropyridopyrazine modulators of GPR6